After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits across the life sciences spectrum are still scrambling to respond to mounting trade pressures. While many unknowns remain, biopharma companies should waste no time in starting to evaluate their options.
In this week’s episode of “The Top Line,” we dig into the latest round of tariffs unveiled by the Trump administration and how they could impact multiple areas of the life sciences industry. Fierce Pharma’s Fraiser Kansteiner sits down with KPMG’s life sciences sector leader Kristin Pothier, who discusses how the current tariffs could pose challenges, how drugmakers and other life sciences companies should respond and whether additional sector-specific duties are on the horizon.
To learn more about the topics in this episode:
- As Trump's 'Liberation Day' tariffs seem to spare pharmaceuticals, threat of industry-specific duties and loopholes persists
- Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey
- Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here'
- Trump again threatens tariffs on pharmaceuticals in 'not too distant' future
This episode is sponsored by Cencora.
See omnystudio.com/listener for privacy information.
Remember Everything You Learn from Podcasts
